[ad_1]
These are preliminary results obtained with volunteers 42 days after the injection of the first dose, the center, the Russian Ministry of Health and the Russian Sovereign Fund involved in the development of the vaccine said in a statement.
The second interim analysis of data from the third phase of clinical trials of the Russian Sputnik V coronavirus vaccine in nearly 19,000 volunteers showed an efficacy of 91.4% on day 28 after the first injection and more than 95%. by day 42 after the first inoculation, reported the Russian portal Actualidad RT.
For its part, the Efe agency reports that in total, 14,095 volunteers received the vaccine and 4,699, the placebo, according to the official note.
Currently, 40,000 volunteers participate in phase three, of which more than 22,000 were injected with the first dose and 19,000 received both the first and second.
During the analyzes, Russian experts have not detected “unforeseen” adverse reactions to Sputnik V vaccine among volunteers who want to be immunized against COVID-19.
Sputnik V costs half the vaccines of Moderna and Pfizer
The FIDR highlighted that the price, less than $ 10 for a dose, is twice less than the vaccines that use mRMA, that is, the American Moderna and Pfizer. The vaccine would be free in Russia.
In addition, Russia has already launched the production of the dehydrated vaccine, based on freeze-drying technology, which will greatly facilitate your transport to international markets, including hard-to-reach regions and others with tropical climates, an advantage over its competitors, which require low storage temperatures, down to minus 70 degrees Celsius, in the case of Pfizer’s, and minus 20 in the case of Pfizer’s drug. Modern
The first batch of Sputnik V for the foreign market will reach customers in January 2021 on the basis of the agreements already signed with foreign partners.
The following video explains the differences between the Sputnik V, Pfizer BioNTech, Moderna, and Oxford vaccines:
[ad_2]
